New combo attack on tough cancers: radiation meets targeted drug
NCT ID NCT06814496
Summary
This study is testing whether it is safe to combine a new targeted drug called tarlatamab with standard radiation therapy. It is for adults with advanced cancers that have a specific protein called DLL3, including certain lung cancers, melanoma, and others. The main goal is to see if the combination causes manageable side effects while trying to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Cancer Center at UMC North/University Medical Center
RECRUITINGTucson, Arizona, 85719, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.